We are live on ! Find out more
ACXP icon

Acurx Pharmaceuticals
ACXP

10 hedge funds and large institutions have $455K invested in Acurx Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

227% more capital inflows, than outflows

Capital inflows: $265K | Capital outflows: $80.9K

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

25% more funds holding

Funds holding: 8 → 10 (+2)

0.37% more ownership

Funds ownership: 0.64% → 1.01% (+0.37%)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HRT Financial
HRT Financial
New York
+$68.3K
2
Tocqueville Asset Management
Tocqueville Asset Management
New York
+$28.5K
3
Patriot Financial Group Insurance Agency
Patriot Financial Group Insurance Agency
Massachusetts
+$14.3K
4
Osaic Holdings
Osaic Holdings
Arizona
+$9.5K
5
BlackRock
BlackRock
New York
+$761

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$76.9K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$4K

ACXP Hedge Fund Activity: Q4 2021 in Review

10 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2021, worth a combined $455K — up 37% from $332K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ACXP positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $68.3K. The largest seller was Millennium Management, cutting an estimated $76.9K.

  • 10 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2021, up from 8 in Q3 2021.
  • Funds reported $455K of Acurx Pharmaceuticals stock for Q4 2021, up 37% quarter-over-quarter.
  • 3 funds opened new Acurx Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +2 holders.
  • The largest Acurx Pharmaceuticals buyer in Q4 2021 was HRT Financial, an estimated $68.3K added.
  • The largest Acurx Pharmaceuticals seller in Q4 2021 was Millennium Management, an estimated $76.9K sold.

Based on aggregated 13F filings for Q4 2021.